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                 A major challenge in the contemporary treatment of cancer including 
chemotherapy, radiation therapy, surgery, immunotherapy etc, is to destroy the tumor tissue 
without affecting the surrounding or distant tissues. An emerging approach to combat 
cancer is anti-angiogenic cancer therapy. Angiogenesis is a physiological process where a 
new blood vessel is formed from a pre-existing vessel (Figure 1). A tumor is nothing but a 
mass of cells undergoing uncontrolled division. Like any other normal cell in our body, 
tumor cells also need nutrients and oxygen for their survival. Our body has its own 
circulatory network to supply nutrients and oxygen to each and every body cell. Tumor 
growth beyond a size of 1-2 mm3 needs assembly of additional blood vessels to supply 
nutrients and oxygen for the rapidly growing tumor cells. Tumor cells secret some growth 
factors (Eg. cytokines, vascular endothelial growth factor etc.) which signal nearby network 
of blood vessels to form sub-vessels directed toward the tumor. 
 
    
 
 
 
 
 
 
 
 
 
 
                              Figure 1: A schematic representation of angiogenesis 
 
              The rationale behind anti-angiogenic cancer therapy is based on destroying the 
blood vessels network surrounding tumor tissue so that the tumor cells will be deprived of 
nutrients and oxygen and consequently, will eventually die out of starvation. Clinical 
success of anti-angiogenic cancer therapy thus critically depends upon selective delivery of 
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cytotoxic genes/drugs to the tumor endothelial cells. The features that distinguish tumor 
blood vessels from resting vessels include over expression of a number of cell surface 
molecular markers such as integrins, endothelial cell growth factor receptors, proteases, 
proteoglycans etc. Integrins, a class of αβ heterodimeric transmembrane glycoprotein 
receptors, mediate cellular adhesion to extra cellular matrix (ECM) or to adjacent cells and 
can regulate cell survival and proliferation by modulating intracellular signaling processes.  
Since many integrins and their specific extracellular matrix (ECM) protein ligands play 
crucial roles in mediating tumor angiogenesis, they are gaining increasing importance as 
drug targets in anti-angiogenic cancer therapy.  Through a series of enzymatic degradations 
of extracellular matrix proteins and binding studies with the resulting peptide fragments, 
Ruoslahti and coworkers showed that a minimum arginine-glycine-aspartic acid (RGD) 
tripeptide sequence is required for the integrin binding property of several ECM proteins. 
 
Gene therapy in anti-angiogenic cancer therapy: Gene Therapy is a promising approach 
for treatment of genetic disorders in which the malfunctioning genes of our body cells are 
replaced or supplemented with the functional copies so that body can produce correct 
enzyme or protein and consequently can eliminate the root cause of the disease. DNA 
(genes), being a poly anionic macromolecule is unlikely to spontaneously enter the 
negatively charged cell surfaces.  Thus, in reality, very few cells receive and express the 
supplemented DNA. Hence is the need for a “transfer vehicle” or a “transfection vector” in 
gene therapy that would condense the macromolecular DNA and help it in crossing the 
plasma membrane barrier.  Currently, there are three main types of gene delivery vectors 
commonly in use: viral, non-viral and physical methods, each having its own merits and 
demerits. During last decade, our laboratory has developed a number of highly efficient 
cationic lipid based non-viral gene delivery reagents. 
 
                   In anti-angiogenic cancer gene therapy, tumor suppressor genes (such as p53, 
Rb, BRCA1 etc.) are delivered to cancer cells as these tumor suppressor genes are present 
in mutated forms in cancer cells. The expression of these known tumor suppressor genes in 
tumor cells causes an aberrant change in cell physiology which eventually leads to cell-
cycle arrest or programmed cell death. Among the tumor suppressor genes, the most widely 
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used gene is p53. The function of p53 and its protein product is to prevent normal cells 
from turning into cancer cells. Inhibition of tumor growth can be achieved by delivering 
wild type p53 gene (in the form of a plasmid) selectively to either cancer cells or to the 
endothelial cells of growing tumor vasculature.  
Signal Transducer and Activator of Transcription 3 (STAT3) and tumor angiogenesis: 
           Signal transducers and activators of transcription (STAT) were identified originally as 
key components of cytokine signaling pathways that regulate gene expression. They are 
activated by phosphorylation on a specific tyrosine residue, usually by receptor-associated 
JAKs (Janus kinases). Activated Stats form homo- or heterodimers and translocate to the 
nucleus in which they interact with consensus promoter sequences and regulate 
transcription (Figure 2). Constitutive activation of one STAT family member, Stat3, has 
been shown to play a key role in promoting proliferation, differentiation, anti-apoptosis, 
and cell cycle progression. In addition to their diverse roles in cell proliferation, 
differentiation, apoptosis, inflamation and oncogenesis, accumulating evidence suggested 
that STATs, mainly STAT3 play a pivotal role in angiogenesis under both physiological 
and pathological conditions.  
 
 
 
 
 
 
 
 
 
 
Figure 2. Mechanism of activation of STATs in signaling by the cytokine receptor 
superfamily. 
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miRNAs: microRNAs (miRNAs) are short (usually 19-25 nucleotides long), non-coding 
RNAs involved in post-transcriptional gene silencing. miRNAs inhibit the expression of 
protein coding genes at the post-transcriptional level in a varieties of eukaryotic organisms 
and reduce the level of their target mRNA transcripts as well as the amount of the encoded 
proteins. The miRNA-coding genes are transcribed by RNA polymerase II (Pol II) into long 
primary transcript of miRNA (pri-miRNA) containing the hairpin structure (Figure 3). 
These pri-miRNAs are subsequently processed into precursors of miRNAs (pre-miRNA) by 
nuclear RNase III Drosha with the aid of cofactor DGCR8. Following nuclear processing, 
the pre-miRNAs are exported to the cytoplasm by a nuclear transport receptor, Exportin-5, 
and Ran-GTP before being processed by the cytoplasmic RNase III Dicer into 21-nuleotide 
mature miRNAs. Finally, the single-stranded miRNA are incorporated into an RNA-
induced silencing complex (RISC) to induce translation suppression or degradation of viral 
or cellular mRNAs depending on the degree of complementary with the target mRNA  
(Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                        Figure 3. Biogenesis of miRNAs 
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                 The mature miRNA then directs RISC to complementary mRNA species. If the 
target mRNA has perfect complementarity to the miRNA-armed RISC, the mRNA will be 
cleaved and degraded. But as in the most common situation in mammalian cells, the 
miRNAs target mRNAs with imperfect complementarity and suppress their translation, 
resulting in reduced expression of the corresponding proteins.  
Dendritic cells based DNA vaccines in cancer immunotherapy:  
                 The essence of DNA vaccination (genetic immunization) is to elicit an effective 
cytotoxic T cells response (CTL response). CTL response results from an interaction 
between naive CD8+ T lymphocytes (those never encountered an antigen) and antigen-
MHC class 1 complex along with the co-stimulatory molecules of antigen presenting cell 
(Figure 4). Though most cell types can process endogeneous antigens and present them to 
CD8+ T lymphocytes via MHC 1-antigen complex, the T cells remain unresponsive to the 
antigen because they do not express co-stimulatory molecules. Expression of co-stimulatory 
(B7.1 and B7.2) molecules is restricted only to professional antigen presenting cells (APCs) 
which include macrophages, B lymphocytes and dendritic cells. Among the APCs, dendritic 
cells provide highest level of co-stimulatory signals and hence are considered as the most 
potent antigen presenting cells and are most inquisitive candidate for DNA vaccine based 
therapies.  This is why dendritic cells are finding increasing exploitations in DNA 
vaccination. The ability of DCs to generate anti-tumor immune responses in vivo has been 
documented in a number of animal tumor models. Most of these experiments involve 
isolation of DCs, followed by loading of DCs with tumor antigens (Ag) and injection of 
Ag-loaded DCs into syngeneic animals as a cancer vaccine.  
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                                                      Figure 4. 
Gene delivery to APCs via mannose receptor. 
                 Mannose receptor, a transmembrane glycoprotein expressed on the cell surfaces of 
antigen presenting cells such as dendritic cells (DCs) and macrophages, selectively binds 
molecules or microorganisms carrying sugars such as mannose, fucose, N-
acetylglucosamine and glucose on their surface through its carbohydrate recognition 
domain.  An emerging strategy for enhancing the efficacy of genetic immunization is based 
on targeting DNA vaccines to APCs via mannose receptor.  For instance, use of mannan (a 
ligand for the mannose receptor) coated liposomes for intranasal delivery of HIV-1 DNA 
vaccine, mannan-coated cationic nanoparticles for topical immunization and mannosylated 
cationic liposomes have been reported for delivering DNA vaccine to APCs. Grandjean and 
coworkers have demonstrated that lysine based clusters of mannose mimicking carbocyclic 
acids such as quinic and shikimic acid are also effective ligands for the mannose receptor of 
dendritic cells. Using a model lipopeptide vaccine, they have demonstrated that such 
glycomimicking amphiphiles hold potential for solubilizing lipopeptide vaccines (which are 
otherwise prone to aggregation) and the resulting mixed micelles are taken up mainly via 
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endocytosis by DCs in vitro.  In addition to their mannose mimicking properties, the 
presence of carboxylic acid functional groups in both shikimic and quinic acids renders 
structural manipulation in their molecular architectures more facile than that in mannose.   
Present thesis: 
Chapter 1A. In the recent years, selective targeting of anticancer drugs or genes to tumor 
vasculatures is accomplished by exploiting unique molecular marker, such as integrins, 
over expressed in tumor endothelial cells. The short amino acid sequence arginine-glycine-
aspartic acid (RGD), the most evolutionary conserved recognition motif for many natural 
integrin-binding extracellular matrix protein ligands such as fibronectin, vitronectin, and 
thrombospondin, has widely been exploited in the past in targeting drugs/genes via integrin 
receptors. The interactions between the short RGD recognition motifs of extracellular 
matrix proteins and the integrin receptors are usually of low affinity, and many integrin 
receptors interact with secondary sites (also known as synergistic sites) of their native 
ligands.  In vivo selection of phage display libraries have been exploited successfully to 
isolate various high affinity conformationally strained cyclic peptides (CX5-7C, peptides 
flanked by a cysteine residue on each side) for integrins capable of selectively homing to 
tumor vasculatures. Studies on phage display libraries have demonstrated that the 
specificity and affinity of integrin binding is remarkably dependent on the nature of the 
amino acid residues lying C-terminal to RGD.  For example, integrin α5β1 has been shown 
to bind with high affinity to peptides containing CRGDGWC motif.  As to the molecular 
level explanation for such high binding affinities of integrin α5β1 to CRGDGWC peptides, 
Humphries and coworkers showed that mutation of Trp157 of α5 subunit to alanine resulted 
into loss of high affinity binding of the α5β1 integrin to RGDGW. These findings are 
consistent with the supposition that Trp157 of α5 subunit participates in a favorable 
hydrophobic interaction with the tryptophan of the RGDGW resulting into its high-affinity 
binding with α5β1 integrin.  Recently, our laboratory has demonstrated that a lipopeptide 
containing a non-cyclic conformationally unstrained simple RGDK tetrapeptide sequence in 
its polar head-group region can selectively target genes to proangiogenic α5β1 integrin 
receptors and can target genes to mouse tumor vasculatures.  Taking such α5β1 integrin 
receptor selective tumor vasculature targeting efficiencies of the simple RGDK-lipopeptide 
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into account, we became interested in probing the integrin receptor selectivity and tumor 
vasculature targeting property of lipopeptide having just the “RGDGW” motif (i.e. without 
the terminal cysteine residues of the “CRGDGWC” obtained from phage display studies 
mentioned above) in its head-group region (Figure 5).  
.   
 
 
 
 
 
                                                            Figure 5.  
                      To this end, we show for the first time that a lipopeptide with just the 
RGDGW motif (without the flanking cysteine groups) covalently attached to the lysine 
residue of a monolysinylated cationic amphiphile (RGDGWK-lipopeptide 1) delivers genes 
to cultured cells preferably via α5β1 integrins. Importantly, remarkable tumor growth 
inhibition was observed when the electrostatic complex of the RGDGWK-lipopeptide 1 and 
the anticancer p53 gene was intravenously administered in C57BL/6J mice bearing the 
aggressive B16F10 tumor.  Immunohistochemical staining of mice tumor cryosections with 
vasculature markers combined with monitoring expression of the green fluorescence protein 
in the same tumor cryosections revealed that the RGDGWK-lipopeptide 1 targets genes to 
tumor vasculatures.  The colocalization of the TUNEL (terminal deoxyuridine triphosphate 
nick-end labeling, a widely used marker of apoptosis) and VE-cadherin (markers of tumor 
endothelial cells) positive cells in tumor cryosections support the notion that the remarkable 
tumor growth inhibition property of the RGDGWK-lipopeptide 1:p53 complex is likely to 
be initiated through apoptosis of the tumor endothelial cells.  
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Chapter 1B. The findings summarized in Chapter 1B demonstrate that remarkable tumor 
growth inhibition in C57BL/6 mice bearing the aggressive B16F10 tumor could be 
achieved by intravenous administration of the electrostatic complex of the RGDGWK-
lipopeptide 1 and a plasmid DNA encoding Stat3 miRNA. To demonstrate that STAT3 is 
constitutively active in cancer cells, we evaluated the STAT3 protein expression level in 
NIH3T3 cells (mouse fibroblast cells) and in B16F10 cells (murine melanoma cells) by 
Western Blot analysis. Keeping the view in mind that in cancer cells, STAT3 dysregulates 
apoptotic genes, we transfected  A549 cells with a complex of RGDGWK-lipopeptide 1 and 
plasmid expression vector which expresses miRNA of STAT3 (pSTAT3 miRNA)  to 
demonstrate that  miRNA  reduces the STAT3 protein level by blocking the STAT3 mRNA  
and hence induces apoptosis. The cellular apoptosis was measured by MTT cell viability 
assay and flow cytometric analysis using Annexin V-FITC and propidium iodide staining. 
Finally, we demonstrate by TUNEL assay that remarkable tumor growth inhibition is 
caused presumably due to apoptosis of tumor endothelial cells. 
     
Chapter 2. Clinical success of DNA vaccination critically depends on mounting effective 
antigen specific cellular immune response which in turn depends upon effective antigen 
presentation by professional antigen presenting cells (dendritic cells and macrophages) to 
naive T cells. Since both dendritic cells and macrophages express endocytic mannose 
receptors on their cell surfaces, delivering genes (antigens) to these cells via mannose 
receptor targeting vectors is a popular strategy in genetic immunization. The non-
carbohydrate carbocyclic Shikimic acid and Quinic acid are potential mannose receptor 
ligands since they possess the vicinal diol functionalities at the C-4 & C-5 positions. More 
importantly, the presence of a carboxylic acid groups in Shikimic & Quinic acid renders 
functionalization more facile than in mannose. Based on this rationale, Chapter 2 delineates 
design and synthesis of a series of novel mannose-mimicking cationic amphiphiles 
containing shikimic acid and quinic acid headgroups (lipids 1-6, Figure 6). As described in 
Chapter 2, the transfection efficacies of these amphiphiles were evaluated in RAW 264.7, 
a mouse macrophage cell line, across the lipid: DNA charge ratios of 8:1-1:1. The results 
demonstrated that lipids 1-6 in combination with equimolar cholesterol as the co-lipid 
exhibited high gene delivery efficacies in RAW 264.7 cells. To demonstrate that lipids 1-6 
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deliver genes to RAW 264.7 cells via mannose receptor, we evaluated the transfection 
efficacies after 30 min. pre-incubation with mannosylated bovine serum albumin (man-
BSA) and in presence of mannan (both are known mannose receptor ligans). The 
transfection efficacies of all the lipids were significantly reduced. Interestingly, the 
transfection efficacies of lipids 1-6 were enhanced in the presence of man-BSA and mannan 
in control NIH3T3 cells (mouse fibroblasts, a non macrophage cell line and does not have 
mannose receptor as revealed by FACS analysis).  
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                                                              Figure 6. 
                 Finally, toward evaluating the therapeutic potential of lipids 1-6 in DC-based 
DNA vaccination, we isolated dendritic cells from mouse bone marrow (mbmDCs), carried 
out phenotypic analysis (presence of mannose receptor, MHC II and co-stimulatory CD86 
marker etc.) by flow cytometry and evaluated  the efficacies of lipids 1-6 in transfecting 
mbmDCs by flow cytometry using a plasmid encoding green fluorescent protein.  
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